Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P01588
UPID:
EPO_HUMAN
Alternative names:
-
Alternative UPACC:
P01588; Q2M2L6; Q549U2; Q9UDZ0; Q9UEZ5; Q9UHA0
Background:
Erythropoietin, encoded by the gene with accession number P01588, plays a pivotal role in regulating erythrocyte proliferation and differentiation. This hormone ensures the maintenance of a physiological level of circulating erythrocyte mass by binding to the erythropoietin receptor (EPOR), leading to EPOR dimerization and JAK2 activation. This cascade activates downstream effectors, including STAT1 and STAT3, integral to erythrocyte development.
Therapeutic significance:
Erythropoietin's involvement in diseases such as Microvascular complications of diabetes 2, Erythrocytosis, familial, 5, and Diamond-Blackfan anemia-like highlights its therapeutic potential. Understanding the role of Erythropoietin could open doors to potential therapeutic strategies for these conditions, particularly in enhancing erythrocyte proliferation and addressing hematologic abnormalities.